
Zhongjie Wang^{1,2,4}, Kelsey N. Thompson^{2,3,4}, Omer Kamer⁸, Danyue Dong^{1,2}, Ehud Rinott⁸, Fenglei Wang^{1,5}, Meir J. Stampfer^{1,5,7}, Iris Shai^{5,8,9,*}, Curtis Huttenhower^{2,3,4,6,*}, Dong D. Wang^{1,2,5,*}¹Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; ²Broad Institute of MIT and Harvard, Cambridge, MA, USA; ³Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA; ⁴Harvard Chan Microbiome in Public Health Center, Harvard T.H. Chan School of Public Health, Boston, MA, USA; ⁵Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; ⁶Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA; ⁷Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; ⁸Faculty of Health Sciences, The Health & Nutrition Innovative International Research Center, Ben-Gurion University of the Negev, Be'er Sheva, Israel; ⁹Department of Medicine, University of Leipzig, Germany

DIRECT-PLUS aFMT Trial


The gut microbiome plays a key role in regulating metabolic health, and dietary interventions can beneficially reshape its composition and function, contributing to weight loss and improved metabolic outcomes. However, weight regain—often observed after 6 months of active intervention—may be partly driven by a reversion of the microbiome toward its baseline state. Autologous fecal microbiota transplantation (aFMT), which uses an individual's own stool collected during a metabolically healthier state, offers a minimal-risk strategy that may preserve diet-induced microbial shifts and reduce weight regain.

Study Design



In this trial, we examined the effects of randomized aFMT vs. Placebo on gut microbiome—particularly strain-level changes—and their role in mitigating weight regain in 90 adults. Participants who **lost 23.5%** of body weight during a 6-month dietary intervention provided fecal samples that were processed into oral capsules.

Synergistic Effects of aFMT + GreenMED on Weight Regain




During the 6-month follow-up, aFMT recipients experienced **significantly less** weight regain compared to placebo, especially when combined with GreenMED.

Individual responses are shown as light lines; bold lines indicate group averages (aFMT vs. Placebo)

Boundaries of Diversity: Quantifying Strain-Level Differences

Precision Strain Delineation with StrainPhlAn


Before tracking strain dynamics, we first had to define what constitutes a unique strain—the foundational pillar of microbial dynamics research. For this purpose, we utilized species-specific phylogenetic genetic distance (nGD) cutoffs using StrainPhlAn v4.1, a validated bioinformatics tool for strain profiling from metagenomic data which leverages single-nucleotide polymorphisms (SNPs) in species-specific marker genes to differentiate bacterial strains.



- Strain cutoff** = minimum of the Youden index (optimizing sensitivity/specificity) or the 5th quantile of distances.
- Strain-level dynamic metrics**: Loss, Gain, Persistence, and Swap.
- Limitation to ambiguous scenarios** (?-?, 1-?, 2-1): StrainPhlAn cannot detect very low abundant strains, while their species are detectable.

aFMT + GreenMED Preserves Diet-induced Strain Changes

Diets Induce Distinct Strain Change Patterns




- Significantly reduced species loss with near-significant gain, but unaffected strain swaps.
- MED/GreenMED enhanced species acquisition while reducing depletion and strain type exchanges.

*p-values derived from linear regression

aFMT+GreenMED Synergistically Preserves Strain-Level Changes

- Overall aFMT population**: aFMT did not differ from placebo in preserving prior diet-induced microbial strain-level changes.
- When combined with GreenMED**: aFMT effectively preserved these strain-level changes for both succession rate and loss-persistence during the follow-up period (Month 6-14).



Succession rate: % of strains that were either gained or swapped during month 0-6 and remained detectable during 6-14.


Loss-Persistence: % of species lost during month 0-6 that persisted between month 6-14.

Left: the overall level
Right: stratified by diets
p.int: interaction effect of aFMT and Diet with linear model

*p-values derived from linear regression models

aFMT + GreenMED Enhances Key Strain Persistence


- Enhanced persistence of specific strains in aFMT, such as *R. lactaris*, *B. longum*, and *B. obeum*, particularly when combined with GreenMED.
- These strains degrade dietary polyphenols → bioactive metabolites (e.g., SCFAs), bridging diet-host health via microbial conversion.
- Highlighting aFMT's potential to sustain key microbial converters of complex dietary compounds.



Left panel: Bar plots display strain counts exhibiting gain-persistence or swap-persistence, and the number of subjects harboring the strains. **Middle panel**: Odds ratio for strain succession rate shows aFMT recipients were X-fold more likely to maintain gained/swapped strains compared to Placebo. **Right panel**: Bubble plot displays the prevalence (% of subjects) harboring persistent strains within overall, treatment, and each diet-treatment group.

Phylogenetic evidence of B. longum strain gain/swap-persistence

Strain-specific intervention efficacy for aFMT and the clinical relevance of precision microbial therapy.



Acknowledgments

The authors gratefully acknowledge the use of the FASRC Cannon cluster supported by the FAS Division of Science Research Computing Group at Harvard University. This work is supported by the research grants: R01NR019992 and RF1AG083764.

Hutlab's Toolbox Powering This Research:

Explore More Hutlab Tools
<https://huttenhower.sph.harvard.edu/tools>

MetaPhlAn

StrainPhlAn

Bluesky

@Hutlab



SCAN ME